|
|
 |
July 15, 2008 |
Now Available:
Watch video podcasts of the 2008 EULAR press conferences
Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment. MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts.
With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.
CME Opportunity:
Pain: FDA Warns of Tendonitis, Tendon Rupture Risk With Certain Antibiotics
Fluoroquinolones get black box warning due to increase risk of tendonitis and tendon rupture...
Pain: Adding Caffeine to Carbs Speeds Muscle Glycogen Recovery After Intense Exercise
About 5 or 6 cups of strong coffee ingested along with carbohydrates after intense exercise can increase muscle glycogen recovery by ≥50% versus carbs alone and might prepare athletes for better performance the following day...
BioPharm Business: Welichem's Phase I Clinical Trial of Topical WBI-1001 Meets Primary, Secondary Objectives in Psoriasis
Welichem Biotech, a biotechnology company developing therapeutic drugs in the fields of autoimmune, inflammatory diseases, and cancer, announced positive results from a phase I clinical trialevaluating topically applied WBI-1001 in psoriasis patients...
BioPharm Business: MediGene Puts Phase I Trial Hold on Due to Patient Death in Study of RhuDex in a New Formulation; Reports Positive Results With RhuDex in Phase IIa Pilot Trial in RA
One study participant suffered a heart problem some days after a scheduled treatment of RhuDex, an orally administered candidate for the treatment of RA; it is currently unclear whether there is any correlation between the death and the drug administration...
BioPharm Business: Wyeth Reports European Commission Announces Marketing Authorization for 50 mg Once-Weekly Enbrel (etanercept) for Patients With Moderate-to-Severe Psoriasis
The European Commission announced a new 50 mg Enbrel (etanercept) once-weekly dosage regimen as an alternative to the currently approved 25 mg Enbrel twice-weekly regimen for the treatment of moderate-to-severe plaque psoriasis...